Business Context and Reporting Period
This Form 8-K is filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on March 12, 2021. The filing reports financial results for the three and twelve months ended December 31, 2020. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Carlsbad, California, and its common stock trades on the NASDAQ Capital Market under the symbol OBLN.
Key Financial Metrics
The filing text provided is a cover sheet and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only indicates that results for the three and twelve months ended December 31, 2020, have been reported.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name is Obalon Therapeutics, Inc. (OBLN), as the request metadata incorrectly listed "Vyome Holdings, Inc."
- Review Exhibit 99.1 (Press Release dated March 12, 2021) for actual financial figures, as they are absent from the 8-K cover text.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the financial data in this filing is not deemed "filed" under Section 18 of the Exchange Act, limiting liability protections compared to standard filings.